These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
229 related items for PubMed ID: 28977029
21. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. Llombart B, Sanmartín O, López-Guerrero JA, Monteagudo C, Serra C, Requena C, Poveda A, Vistós JL, Almenar S, Llombart-Bosch A, Guillén C. Histopathology; 2009 Jun; 54(7):860-72. PubMed ID: 19635106 [Abstract] [Full Text] [Related]
22. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Ono T, Noguchi R, Osaki J, Akiyama T, Adachi Y, Kojima N, Toda Y, Fukushima S, Yoshimatsu Y, Yoshida A, Kawai A, Kondo T. Hum Cell; 2024 May; 37(3):854-864. PubMed ID: 38372888 [Abstract] [Full Text] [Related]
23. Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing. Peng C, Jian X, Xie Y, Li L, Ouyang J, Tang L, Zhang X, Su J, Zhao S, Liu H, Yin M, Wu D, Wan M, Xie L, Chen X. Br J Dermatol; 2022 Jun; 186(6):997-1009. PubMed ID: 35441365 [Abstract] [Full Text] [Related]
25. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing. Hong JY, Liu X, Mao M, Li M, Choi DI, Kang SW, Lee J, La Choi Y. PLoS One; 2013 Jun; 8(7):e69752. PubMed ID: 23922791 [Abstract] [Full Text] [Related]
28. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data--a study from the French Federation of Cancer Centers Sarcoma Group. Terrier-Lacombe MJ, Guillou L, Maire G, Terrier P, Vince DR, de Saint Aubain Somerhausen N, Collin F, Pedeutour F, Coindre JM. Am J Surg Pathol; 2003 Jan; 27(1):27-39. PubMed ID: 12502925 [Abstract] [Full Text] [Related]
29. Risk factors for distant metastasis of dermatofibrosarcoma protuberans. Hayakawa K, Matsumoto S, Ae K, Tanizawa T, Gokita T, Funauchi Y, Motoi N. J Orthop Traumatol; 2016 Sep; 17(3):261-6. PubMed ID: 27289468 [Abstract] [Full Text] [Related]
30. Fine-needle aspiration of dermatofibrosarcoma protuberans metastasizing to hemithorax with superior vena cava compression: Case report and literature review. Banach BS, Antic T, Bridge JA, Cipriani NA, Frye L, Krausz TN, Biernacka A. Diagn Cytopathol; 2019 Aug; 47(8):797-802. PubMed ID: 30919592 [Abstract] [Full Text] [Related]
31. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, Kellner I, Leverkus M, Becker JC, Ströbel P, Schadendorf D. Clin Cancer Res; 2014 Jan 15; 20(2):499-510. PubMed ID: 24173542 [Abstract] [Full Text] [Related]
33. Determination of COL1A1-PDGFB breakpoints by next-generation sequencing in the molecular diagnosis of dermatofibrosarcoma protuberans. Zhu R, Yan J, Li B, Tan F, Yan W, Shen J, Fan L, Ding L, Chen Y, Tang Y, Liu Y, Bai Y. Exp Mol Pathol; 2021 Oct 15; 122():104672. PubMed ID: 34371012 [Abstract] [Full Text] [Related]
34. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate. Kambayashi Y, Kasahara Y, Ohuchi K, Amagai R, Hashimoto A, Asano Y, Fujimura T. Dermatol Ther; 2022 Oct 15; 35(10):e15736. PubMed ID: 35898161 [Abstract] [Full Text] [Related]